Key facts
- It has raised $6.9M; the latest was Later Stage VC ($6.9M) in Jan 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for CQENS
- ·The full record, as it builds
Funding rounds
No funding rounds for CQENS are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CQENS
Developer of inhalation technology intended to reduce harm and improve public health. The company uses proprietary, patented technology to formulate methods of heating plant-based consumables or medicant-infused substrates, helping herbal, pharmaceutical, medical, recreational, and lifestyle products companies to produce aerosols for safe, effective, and efficient inhalation of plant constituents.
- Sector
- Business Products and Services (B2B)
- HQ
- Minneapolis, MN, United States
- Founded
- 2009
- Employees
- 4
- Website
- cqens.com/
- Ownership
- Privately Held (backing)
CQENS doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CQENS shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CQENS in its N-PORT filings yet. We sweep new filings monthly.